Skip to main content

INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation.

Publication ,  Conference
Mellinghoff, IK; Van den Bent, MJ; Clarke, JL; Maher, EA; Peters, KB; Touat, M; De Groot, JF; De La Fuente, MI; Arrillaga-Romany, I; Wick, W ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
2020

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

2020

Volume

38

Issue

15

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mellinghoff, I. K., Van den Bent, M. J., Clarke, J. L., Maher, E. A., Peters, K. B., Touat, M., … Cloughesy, T. F. (2020). INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).
Mellinghoff, Ingo K., Martin J. Van den Bent, Jennifer Leigh Clarke, Elizabeth Anne Maher, Katherine B. Peters, Mehdi Touat, John Frederick De Groot, et al. “INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.
Mellinghoff IK, Van den Bent MJ, Clarke JL, Maher EA, Peters KB, Touat M, De Groot JF, De La Fuente MI, Arrillaga-Romany I, Wick W, Ellingson BM, Schoenfeld S, Tai F, Le K, Lu M, Steelman L, Hassan I, Pandya SS, Wen PY, Cloughesy TF. INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation. JOURNAL OF CLINICAL ONCOLOGY. 2020.

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

2020

Volume

38

Issue

15

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences